Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

× No keyword cloud information.

19 in total

1. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Authors: J Simiand; M Keane; P E Keane; P Soubrié
Journal: Behav Pharmacol Date: 1998-03 Impact factor: 2.293

2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors:
Journal: Circulation Date: 2002-12-17 Impact factor: 29.690

Review 3. Weight change and atypical antipsychotic treatment in patients with schizophrenia.

Authors: B Jones; B R Basson; D J Walker; A M Crawford; B J Kinon
Journal: J Clin Psychiatry Date: 2001 Impact factor: 4.384

4. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.

Authors: Miwako Shobo; Hiroshi Yamada; Takuma Mihara; Yuji Kondo; Megumi Irie; Katsuya Harada; Keni Ni; Nobuya Matsuoka; Yukihiko Kayama
Journal: Behav Brain Res Date: 2010-09-15 Impact factor: 3.332

5. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward.

Authors: Stephen V Mahler; Kyle S Smith; Kent C Berridge
Journal: Neuropsychopharmacology Date: 2007-04-04 Impact factor: 7.853

Review 10. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health.

Authors: Daniela Cota
Journal: Diabetes Metab Res Rev Date: 2007-10 Impact factor: 4.876

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

1. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Review 3. Weight change and atypical antipsychotic treatment in patients with schizophrenia.

4. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.

5. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward.

6. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition.

Review 7. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.

Review 8. Rimonabant for the treatment of overweight and obese people.

9. Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.

Review 10. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health.